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Background: Human African Trypanosomiasis (HAT) and leishmaniasis are two of the most
neglected challenging tropical diseases, caused by the kinetoplastid parasites Trypanosoma and
Leishmania species, respectively. For both of these complex disease spectra, treatment options
are limited and threatened by drug resistance, justifying urgent new drug discovery efforts.
Purpose: In the present studywe investigated the antitrypanosomal and antileishmanial activity of
a series of 21 symmetrical α,β-unsaturated carbonyl-based compounds, each featuring two
3-methoxybenzene attached to a central cyclohexanone, tetrahydro-4-pyranone scaffold or 4-piper-
idone ring. Structure-activity relationships were explored with respect to substitution on positions
3, 4 and 6 of the terminal 3-methoxybenzyl groups, and seven types of central ring.
Results: Compounds 3a, 3o, 3s and 3t, showed broad anti-kinetoplastid activity against all
species and strains tested.
Conclusion: Compound 3o featuring N-methyl-4-piperidone was found to be the most
potent analog and therefore can serve as a potential lead for the development of new drug
candidates for trypanosomiasis and leishmaniasis.
Keywords: protozoan parasites, sleeping sickness, -α,β-unsaturated carbonyl-based
compounds, cyclohexanone, piperidine
Introduction
Leishmaniasis and trypanosomiasis are arthropod-borne diseases of humans and
animals caused by infection with protozoan hemoﬂagellates of the genus
Leishmania and Trypanosoma, respectively. The two genera are incorporated into
the family Trypanosomatidae, order Kinetoplastida. The most recent information
released by the World Health Organization (WHO) shows that the extraordinary
efforts at control, implemented at the peak of the epidemic in the early 2000s is
reducing the number of new cases of HAT.1 However, HAT has been close to
eradication half a century before now, and the subsequent discontinuation of control
programs allowed the disease to re-emerge to epidemic levels throughout Africa,
which had then to be combatted with the same drugs that were introduced in the
1930s and before.2,3 Combination of nifurtimox and eﬂornithine (NECT) is pre-
sently suggested for the treatment of the late stage HAT because NECT treatment is
simpler, safer, shorter and less expensive than single-agent eﬂornithine (DFMO).4
Moreover, animal trypanosomiasis is a very important disease of livestock causing
billions of dollars in economic damage and spreading from Africa to areas from
South America to East Asia.5
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Leishmaniasis is caused by approximately 20
Leishmania species, which are transmitted by phleboto-
mine sandﬂies.6,7 According to the World Health
Organization (WHO) around 1 million new cases, which
cause around 30,000 deaths, occur every year around the
world, mostly in the tropics or sub-tropics. The disease is
still spreading geographically and is far from being con-
trolled, due in large part to ecological and climate changes,
and affects predominantly poor populations but, increas-
ingly also eastern and southern Europe.8,9 Among indivi-
dual infectious diseases as the ninth largest disease burden,
leishmaniasis should not be overlooked in deliberations of
tropical disease urgencies.10,11
In recent years new α,β-unsaturated carbonyl-based
compounds have been extensively investigated as multi-
functional drug candidates. Previously we synthesized and
evaluated several series of such compounds for anti-
inﬂammatory,12 anticancer,13,14 immunomodulatory15,16
and anti-Alzheimer,17,18 identifying potent activities. Here,
we have selected a series of such α,β-unsaturated carbonyl-
based compounds for evaluation of their effects against
a number of Leishmania and Trypanosoma strains including
the well-characterized multi-drug resistant Trypanosoma
brucei clonal line B48, which displays very high levels
resistance to the two major classes of trypanocides, the
diamidines and the melaminophenyl arsenicals, due to the
loss of HAPT1 and TbAT1/P2 drug transporters.19
Materials and methods
Materials
Synthetic α,β-unsaturated carbonyl-based compounds with
cyclohexanone, 4-piperidone or tetrahydro-4-pyranonemoiety
were synthesized (Scheme 1), characterized and reported by us
previously.20 Stock solutions were prepared for each tested
compound and diluted with complete medium for antiparasite
testing, ensuring that the ﬁnal DMSO concentration did not
exceed 1% in the ﬁnal conditions. Eﬂornithine (Sigma-Aldrich
Ltd., Gillingham, UK) and pentamidine (Sigma-Aldrich Ltd.,
Gillingham, UK), themost widely used drugs for the treatment
of HATwere selected as positive control.
Cell culture
Trypanosoma brucei bloodstream forms (BSF)
in-vitro
The selected compounds were tested on bloodstream
forms of two strains of Trypanosoma brucei: a standard
drug-sensitive wild-type strain of Trypanosoma brucei
brucei (Lister s427-WT) and B48, which was adapted
from the clone TbAT1-KO by deletion of the TbAT1
drug transporter,21 itself derived from s427WT by removal
of the TbAT1 gene,21 by prolonged exposure to pentami-
dine in vitro.19 Thus, these cells have neither TbAT1/P2
transporter nor the high afﬁnity-pentamidine transporter
(HAPT1) genes.19,22 Both strains were cultured in HMI-9
medium (pH 7.4) supplemented with 10% heat-inactivated
Fetal Calf Serum (FCS, BioSera) and 14 µl/L of 13.4 M β-
mercaptoethanol (Sigma), as described by Hirumi and
Hirumi.23 In a ﬂow cabinet through ﬁltration medium
was sterilized. T. b. brucei cultures were incubated at
37 ºC and 5% CO2 and passaged in vented ﬂasks three
times a week.
Leishmania major and leishmania mexicana
promastigotes
Leishmania major strain Friedlin (LmjF) and Leishmania
mexicana (strain MNYC/BZ/62/M379) were cultured in
essential medium (HOMEM) and 10% FCS, pH 7.4, in
plastic ﬂasks at 25 °C. The cultures were passed to fresh
medium three times per week, exactly as described
previously.24
Alamar blue assay
Resazurin (Alamar Blue) is commonly used as a metabolic
function indicator. It is a non-ﬂuorescent, blue dye that is
mixed with cell cultures containing various drug concentra-
tions, to determine the sensitivity of African trypanosomes
or Leishmania cultures to the test compounds in vitro.25,26
Living cells metabolize the resazurin to red and ﬂuorescent
resoruﬁn. Preparation of Alamar Blue reagent involves the
dissolution of 12.5 milligrams of Resazurin sodium salt
(Sigma) in 100 mL of phosphate-buffered saline (PBS) of
pH 7.4, which is then ﬁlter-sterilized and stored in the dark
at 4 ºC. For T. b. brucei bloodstream forms the assays were
performed as described27 in 96-well plates with 1 × 105 cell/
well in the presence of 23 doubling dilutions of test com-
pound, and one well for each dilution series receiving
growth medium only, for 48 h at 37 °C/5% CO2. The
Alamar blue solution was added for a further 24 h incuba-
tion before ﬂuorescence was measured in a FLUOstar
Optima plate reader (BMG Labtech, Durham, NC, USA),
λex 540 nm, λem 590 nm. EC50 values were calculated by
non-linear regression to a sigmoidal curve with variable
slope using Prism 5.0 (GraphPad Software Inc., San
Diego, CA, USA). For Leishmania promastigotes the pro-
cedure was slightly adapted24 and the ﬁnal density was
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1 × 106 cell/well with the initial incubation for 72 h followed
by incubation with Alamar blue for 48 h as total of 120 h.
All assays were repeated at least 3 times independently and
each were positively controlled with pentamidine and
eﬂornithine.
Results and discussion
In the present study, the effect of synthetic α,β-unsaturated
carbonyl-based compounds on the growth of promasti-
gotes of L. major, L. mexicana and different strains of
Trypanosoma brucei brucei was evaluated in vitro.
Structures of all tested compounds are shown in Table 1
while the antitrypanosomal and leishmanicidal activities of
compounds are shown in Table 2.
Antitrypanosomal activity
In vitro trypanocidal properties of synthetic α,β-
unsaturated carbonyl-based compounds were assessed for
two different types of Trypanosoma brucei brucei where
one was WT and second was the highly resistant
T. b. brucei clonal line B48 (Table 2). In this assay,
reference drugs eﬂornithine and pentamidine were used
as positive controls. Pentamidine was found very potent
with EC50=0.005 µM for wild type and 0.37µM for clonal
line B48 (P<0.001), while EC50=19.47 and 22.6 uM were
determined for eﬂornithine-treated WT and B48 (P>0.05)
parasites, respectively. Among the tested compounds,
twelve derivatives inhibited both strains, with EC50 values
within 2-fold different for the two strains, as compared to
a 74-fold (increase) difference for pentamidine, showing
that this class of compounds is not cross-resistant with
diamidines and melaminophenyl arsenicals (Bridges et al,
2007). The highest inhibitory activity was exhibited by 3o
(EC50=1.7 µM) for clonal line B48 and second most strong
inhibitor was synthetic compound 3a with an EC50 value
of 2.8 µM, closely followed by 3s showing inhibition with
an EC50 of 3.55 µM.
An interesting structure-activity relationship was observed
for synthetic α,β-unsaturated carbonyl-based derivatives.
Based on their chemical structure all 21 compounds can be
divided into sevenmain groups, with three compounds in each
group. Seven groups are suggested on the basis of R1 substitu-
tion in the central ring that linked the two substituted 3-meth-
oxybenzenemoieties. In each of the 7 groups the aromatic ring
substitutions R1ʹ, R3ʹ, R4ʹ were kept the same [(i) H/H/Cl; (ii)
H/OCH3/Cl; (iii) OCH3/OCH3/Br], allowing direct deduction
of the role of the central ring modiﬁcations for each set of
aromatic ring substitutions.
It is immediately clear that the R1 position substitution
in the central linker played a vital part in the biological
properties of these types of compounds, as we have pre-
viously reported for anti-inﬂammatory activities.28
However, in the case of anti-inﬂammatory and anticancer
activities20 different substitutions correlated with highest
potency.
All three compounds with a tetrahydro-4-pyranone lin-
ker, 3s, 3t and 3u, exhibited good activity, meaning that
oxygen at the R1 position was favorable for activity
against both strains of T. b. brucei. Within this group, 3s
displayed the highest activity, indicating that addition of
Rʹ3 and Rʹ4 methoxy groups were not favored with this
central ring. Among the other six linkers, the one with N-
CH3 at R1 (3m-3o) exhibited the strongest trypanocidal
activity and 3o was the most active compound in the entire
series (EC50(WT) =1.83±0.06). However, for the
1-methyl-4-piperidones the activity dramatically improved
with the sequential addition of methoxy groups at Rʹ3 and
Rʹ4, which appears to indicate that these compounds may
have a different target than the tetrahydro-4-pyranones,
where the methoxy groups had a deleterious effect. This
notion is strengthened by the understanding that the tetra-
hydropyran oxygen is a strong H-bond acceptor, whereas
the ring nitrogen of 1-methylpiperidone is unable to
engage in similar H-bonding; similar reasoning can be
applied to the methoxy substitution. Thus, the potential
interactions of the most active compounds in these groups,
3s and 3o, respectively, with a cellular target would be
very different, yet their trypanocidal activities are similar.
R1
O
+ i
3a-u
R1
O
2
H
O
R'4
R'3
OCH3
R'1
R'4
R'3
OCH3
R'1
1
R'4
R'3
OCH3
R'1
Scheme 1 Synthesis scheme of α,β-unsaturated carbonyl-based compounds. Reagents and conditions: (i) NaOH, EtOH, room temperature.
Dovepress Alkhaldi et al
Drug Design, Development and Therapy 2019:13 submit your manuscript | www.dovepress.com
DovePress
1181
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
97
 o
n 
11
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Indeed, the favorability of the methoxy substitutions
appeared to differ depending on the identity of R1, probably
because this inﬂuenced the 3D structure through the orienta-
tion/rotation of the aromatic rings relative to the central
structure and each other (Figure 1). These observations
mean that further extension of the SAR in this series should
focus on one central group, optimizing the substituents on the
aromatic rings, especially as the importance of the 2ʹ meth-
oxy and the 1ʹ halogen for antitrypanosomal activity cannot
be assessed from the current as they are present in all deri-
vatives. However, the present data (1) reveal which central
rings are optimal, (2) provide a limited SAR starting point for
Table 1 Structures of synthetic α,β-unsaturated carbonyl based compounds (cyclohexanone, tetrahydro-4-pyranone scaffold and
4-piperidone derivatives)
3a-u
R1
O
R'4
R'3
OCH3
R'1
R'4
R'3
OCH3
R'1
No. Compound R1 Rʹ4 Rʹ3 Rʹ1
3a CH2 H H Cl
3b CH2 H OCH3 Cl
3c CH2 OCH3 OCH3 Br
3d CH CH3 H H Cl
3e CH CH3 H OCH3 Cl
3f CH CH3 OCH3 OCH3 Br
3g
CH
H H Cl
3h
CH
H OCH3 Cl
3i
CH
OCH3 OCH3 Br
3j NH H H Cl
3k NH H OCH3 Cl
3l NH OCH3 OCH3 Br
3m CH3N H H Cl
3n CH3N H OCH3 Cl
3o CH3N OCH3 OCH3 Br
3p
N
H H Cl
3q
N
H OCH3 Cl
3r
N
OCH3 OCH3 Br
3s O H H Cl
3t O H OCH3 Cl
3u O OCH3 OCH3 Br
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Table 2 Effect of α,β-unsaturated carbonyl based compounds on Trypanosoma brucei brucei bloodstream forms and Leishmania
mexicana and Leishmania major strains
Compounds Trypanosoma brucei brucei bloodstream
forms
EC50 (µM)
Leishmania promastigotes
EC50 (µM)
WT B48 L. major L. mexicana
3a 2.81±0.71 5.70±0.66 12.13±1.67 10.03±0.67
3b 17.92±1.12 23.42±2.34 19.36±4.06 15.32±2.44
3c >100 >100 >100 >100
3d >100 91.95±3.10 >100 >100
3e 4.35±0.15 4.45±0.09 >100 >100
3f >100 >100 >100 >100
3g 35.93±1.01 31.49±0.37 >100 >100
3h >100 >100 >100 >100
3i >100 >100 >100 >100
3j >100 >100 >100 >100
3k 5.59±0.08 8.47±0.79 41.55±2.46 >100
3l >100 >100 >100 >100
3m >100 >100 >100 >100
3n 15.15±1.60 11.60±0.62 >100 >100
3o 1.83±0.06 1.75±0.05 3.02±0.10 4.12±0.69
3p 7.94±0.24 7.47±0.09 16.85±2.80 25.57±4.93
3q >100 >100 >100 >100
3r 17.36±2.75 8.22±1.20 >100 >100
3s 3.36±0.59 3.55±0.18 10.56±0.96 22.63±0.75
3t 4.12±0.12 4.04±0.11 4.89±0.42 6.37±0.36
3u 10.27±2.15 6.66±0.67 38.40±8.69 89.04±3.95
Eﬂornithine 19.47±2.45 22.60±1.13 - -
Pentamidine 0.005±0.000 0.37±0.01 4.34±0.17 1.25±0.11
Notes: All EC50 values were obtained using the Alamar blue assay and are given as averages in µM (±SEM), of 3 independent determinations.
Abbreviations: WT, wild-type sensitive control strain; B48, multi-drug resistant clone.
OCH
3
OCH
3
OCH
3 CH3
OCH
3
OCH
3
OCH
3
H
3
CO
H
3
CO
Br Br
O
3s 3o
N
O
OCI CI
Figure 1 Energy-minimized 3D structures of compounds 3s and 3o, produced using Chem3D Ultra 10.0 (CambridgeSoft).
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these scaffolds and (3) establish that even with the very
limited exploration of this chemical space several trypano-
cides with EC50 values in the range 1–5 µM could be identi-
ﬁed. This activity is obviously much superior to eﬂornithine
(Table 2) and close to that of the standard veterinary trypa-
nocide diminazene aceturate as well.21 Moreover, the α,β-
unsaturated carbonyl-based compounds were not cross-
resistant with diamidines and arsenical trypanocides as they
displayed the same activities against the multi-drug resistant
clone B48.
Antileishmanial activity
The extracellular insect-infective promastigote form of
Leishmania is addressed in many drug screening assays
against Leishmania which can be performed readily, thus
being additional suitable for automation even though the
Leishmania parasite exists in the human host in its intra-
macrophage amastigote form.29 In the current study, all
synthetic α,β-unsaturated carbonyl-based compounds
were tested on promastigotes of L. major and
L. mexicana (Table 2). Eight synthetic compounds
showed inhibition, with EC50 values in the range 3 to
41.5 µM for L. major and very similar activities against
L. mexicana. The most active compound was again 3o
(EC50 3.02±0.10 µM), which performed superior to the
positive control pentamidine (EC50 4.34±0.17 µM). The
activity was generally below that displayed for
T. b. brucei but in general the compounds most active
against the trypanosome strains were also the most active
against both Leishmania species (mexicana & major). In
fact, we found very strong correlation between the trypa-
nocidal and antileishmanial activity of these compounds,
as 3a, 3b, 3o, 3p, 3s, 3t and 3u displayed activities
against two trypanosoma strains as well as two distinct
Leishmania species, and some compounds like 3c, 3f, 3h,
3i, 3j, 3m and 3q have no effect against any of the
parasites. For antileishmanial activity, again tetrahydro-
pyran-4-one backbone was found best inhibitor among all
other linkers as all three compounds bearing this back-
bone were found to have various levels of activity - yet
the best activity was by 3o, with a 1-methyl 4-piperidone
backbone.
Conclusion
In this study some synthetic α,β-unsaturated carbonyl-
based compounds with three types of substitution pattern
and seven types of central linker have been identiﬁed
with potential applications against trypanosomiasis and
leishmaniasis. Total twenty-one derivatives were evalu-
ated and twelve of them exhibited good trypanocidal and/
or antileishmanial activities. The most promising results
were obtained for compound 3o that showed the best
inhibition of Trypanosoma brucei brucei wild type
(WT) as well as T. b. brucei clonal line B48 and strong
activity against Leishmania promastigotes, exceeding the
efﬁcacy of the positive control. Further studies should be
conducted to further explore the SAR and better under-
stand the mechanism of action of these molecules. Thus,
these series of new α,β-unsaturated carbonyl-based could
be considered as promising hit compounds against leish-
maniasis and trypanosomiasis requiring further hit opti-
mization and safety evaluations.
Disclosure
The authors report no conﬂicts of interest in this work.
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